Panoramica dell'azienda
Pharvaris N.V. operates as a late-stage biopharmaceutical entity dedicated to the research and commercialization of therapeutic interventions designed for rare diseases characterized by unmet medical needs, specifically targeting conditions mediated by bradykinin such as angioedema. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address niche markets where traditional pharmaceutical solutions may be insufficient or non-existent. As of the latest available data, the company maintains a total market capitalization of $1.78 billion and employs a workforce of 118 individuals to advance its pipeline, which includes the development of deucrictibant, a small molecule bradykinin B2-receptor antagonist. The market cap of $1.78 billion indicates that the entity commands a significant valuation relative to its current operational scale and revenue generation capabilities, while the absence of reported annual revenue figures suggests that the company is likely in a phase of capital-intensive development rather than established commercial profitability. This financial structure is typical for biotechnology firms that prioritize R&D expenditure and clinical trial completion over immediate cash flow generation, reflecting a strategic focus on long-term asset creation rather than short-term revenue expansion.
Salute finanziaria
The financial statements for Pharvaris N.V. reflect a net income of -$163,719,488 over the trailing twelve months, with an EBITDA of -$167,259,872, illustrating a substantial gap between gross revenue and final profitability that points to significant operating expenses or costs of goods sold that erode the bottom line before interest and taxes. Although the gross margin, operating margin, and profit margin are all reported as 0.0%, these figures indicate that the company is currently operating at a stage where revenues do not yet cover variable and fixed costs effectively, or that the revenue base is insufficient to generate positive margins in the current reporting period. The company reports a free cash flow of -$76,153,248, which signifies a net outflow of cash from operations and investing activities, implying that the firm must rely on external financing or existing cash reserves to fund its ongoing research and development efforts. Despite the negative free cash flow, the company holds a cash balance of $329.29 million, which provides a buffer against current obligations, while the total debt stands at $578,657, creating a distinct disparity between liquid assets and liabilities. The debt-to-equity ratio of 0.18 further suggests a conservative balance sheet structure where equity significantly outweighs debt obligations, minimizing the risk of financial distress despite the lack of positive operating cash flow. Additionally, the current ratio is reported at 12.86, an exceptionally high figure that indicates robust short-term liquidity and the ability to meet current liabilities many times over with available current assets. Return on equity stands at -53.8% and return on assets at -32.1%, metrics that reveal that management is currently utilizing shareholder and asset bases to generate losses rather than profits, a common characteristic in early to late-stage biotechnology development phases before a product achieves widespread commercial adoption.
Valutazione del valore
The valuation metrics for Pharvaris N.V. present a complex picture, with a trailing twelve-month P/E ratio listed as N/A due to the lack of net income, while the forward P/E ratio is calculated at -8.59, indicating that the market is pricing in future earnings recovery that has not yet materialized in the trailing period. The price-to-book ratio is 4.93, suggesting that the market is valuing the company at nearly five times its book value, which often reflects the high potential value of intangible assets like intellectual property and clinical data that are not fully captured on the balance sheet. Alternative valuation measures such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -8.66, further highlight the challenges in applying traditional multiple-based valuation methods to a company with negative earnings and no reported sales. The stock price has exhibited significant volatility over the past year, trading between a 52-week low of $11.51 and a 52-week high of $29.80, meaning the current valuation sits within a range that has seen more than double the lowest point in the recent trading history. The beta value of -2.71 is a statistically unusual negative figure that implies the stock's price movements have historically moved inversely to the broader market or specific benchmark indices, resulting in a volatility profile that is magnified and opposite to general market trends.
Growth & Income
Pharvaris N.V. reports N/A for both revenue growth year-over-year and earnings growth year-over-year, as the company has not yet achieved consistent positive revenue streams or earnings that would allow for meaningful year-over-year percentage comparisons in the traditional sense. Consequently, the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which indicates that all available earnings, including those used to offset losses, are being retained and reinvested into the research and development pipeline rather than distributed to shareholders. The absence of a dividend payout ratio confirms that the firm prioritizes capital allocation toward expanding its therapeutic portfolio and funding clinical trials over providing income to investors. The overall growth and income profile is therefore defined entirely by the potential future commercialization of its asset deucrictibant and the successful navigation of regulatory hurdles, rather than by historical growth rates or current income distribution.